Chief Regulatory Officer
Anne-Virginie Eggimann joins Tessera after nearly 11 years as Chief Regulatory Officer at bluebird bio, Inc. Ms. Eggimann has more than 20 years of experience in the development of innovative medicinal products, with a notable record of designing and executing robust regulatory strategies for bringing oncology products, cell and gene therapies, and orphan drugs from early development to market. During her tenure at bluebird bio, she has played a key role in partnering with regulators to bring the company’s pioneering gene therapy products in severe genetic diseases and oncology from preclinical development to registration, leading to several recent approvals in Europe and the U.S. Ms. Eggimann has shaped bluebird’s regulatory policy efforts and is actively engaged with regulatory authorities and trade associations to continue to positively influence the evolving regulatory environment for the field of cell and gene therapy. Prior to joining bluebird, Ms. Eggimann was an Executive Director at Voisin Consulting Life Sciences, leading complex development projects with biotech companies in both the US and Europe. During her decade with Voisin, she contributed to the organization’s global growth from three employees to more than 70. Ms. Eggimann currently serves on the board of Codiak Biosciences. She holds a Master of Science from the UCLA School of Public Health, and a B.S. in Chemical Engineering from the California Institute of Technology.